Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
Milan, Italy, 1 December 2009 - BioXell S.p.A. (SIX: BXLN) announced
today the termination of the working relationship with Laurence H.
Skillern, Chief Medical Officer.
Mr. Skillern joined BioXell as Chief Medical Officer as of February
1, 2009. His function has been terminated by both parties by mutual
agreement effective November 30, 2009.
About BioXell
BioXell S.p.A. (SIX: BXLN) is a listed biopharmaceutical company that
focused on the discovery and development of drugs that exploit novel
mechanisms of action. The Company is currently pursuing efforts to
outlicense its monoclonal antibody BXL1H5 for the treatment of
chronic pain. On 18 November 2009, BioXell announced that its Board
of Directors supports the intended public takeover by Cosmo
Pharmaceuticals S.p.A. The offer is expected to be launched in
December 2009 and will be closed in March 2010.
BioXell was founded in 2002 as a spin-out from Roche. In June 2006,
BioXell listed its shares on the main segment of the SIX Swiss
Exchange. The Company is located in Milan, Italy.
More information on BioXell can be found at: www.bioxell.com
For further information, please contact:
BioXell
Dynamics Group SA
Alvise Sagramoso, Chief Administrative
Officer Christophe Lamps
Tel: +39 (0)2 210 49
550 Tel:
+41 (0)22 308 62 22
Fax: +39 (0)2 700 59
926
Fax: +41 (0)22 308 62 36
alvise.sagramoso@bioxell.com cla@dynamicsgroup.ch
This press release can be downloaded at www.bioxell.com.
Disclaimer
This press release does not constitute or form part, or all, of any
offer or invitation to sell or issue, or any solicitation of any
offer to purchase or subscribe for, any securities, nor shall part,
or all, of these materials or their distribution form the basis of,
or be relied on in connection with, any contract or investment
decision in relation to any securities. This press release contains
forward-looking statements based on the currently held beliefs and
assumptions of the management of BioXell, which are expressed in good
faith and, in their opinion, reasonable. Forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance,
or achievements of BioXell, or industry results, to differ materially
from the results, financial condition, performance or achievements
expressed or implied by such forward-looking statements. Given these
risks, uncertainties and other factors, recipients of this document
are cautioned not to place undue reliance on these forward-looking
statements. BioXell disclaims any obligation to update these
forward-looking statements to reflect future events or developments.
--- End of Message ---
bioXell S.p.A
via Olgettina 58 Milan Italy
WKN: A0J3MW; ISIN:
IT0004069933 ;
Listed: Main Market in SIX Swiss Exchange;
